We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A ruling by the federal appeals court recently to uphold the denial of a patent extension for a combination drug could have a chilling effect on pharmaceutical and biotechnology firms working on new products that combine previously existing drugs.
Mylan Laboratories has lost a patent challenge to market a generic version of Johnson & Johnson’s (J&J’s) lucrative pain drug patch Duragesic (fentanyl), but the generic firm insists it will launch the product six months sooner than J&J says is allowed.
A federal appeals court has rejected an argument by Novartis that the physiological interaction between a competitor’s cyclosporine product and a patient’s body infringed on one of its patents.
The U.S. Court of Appeals for the Federal Circuit has upheld the denial of a patent extension to combination drugs, a decision that is expected to have a chilling effect on pharmaceutical and biotechnology companies working on new products that combine previously existing drugs.
A recent ruling from the U.S. Court of Appeals for the Federal Circuit shoots down the argument that the combination of previously existing drugs creates a new product eligible for a patent term extension.
Drugmaker Kos Pharmaceuticals has filed a fourth patent infringement lawsuit against Barr Pharmaceuticals over the firm’s bid to market a generic version of Kos’ cholesterol drug Niaspan (niacin).
Teva Pharmaceutical has launched the first generic version of Purdue Pharma’s lucrative pain drug OxyContin (oxycodone) in 80-mg strength extended-release tablets, even as patent battles over the drug continue.
A recent federal appeals court ruling upholding the denial of a patent extension for a combination drug could have a chilling effect on pharmaceutical and biotechnology companies working on new products that combine previously existing drugs.
A federal judge has ruled that Mylan Laboratories' generic version of Johnson & Johnson's (J&J's) lucrative pain drug patch Duragesic (fentanyl) infringes on the product's patent, but Mylan insists it will launch the drug six months sooner than J&J says is allowed.